Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Seres Therapeutics, Inc. (MCRB) is a Biotechnology company based in US with a market capitalization of $50.8M. The company generated $865K in free cash flow. This page tracks MCRB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 103 employees · IPO Jun 26, 2015
Valuation
Valuation & price
$7.64as of May 17, 2026· -73.3% vs 52w high
11.9
P/E ratio
Latest-FY diluted EPS
1.15
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$50.8M
Market cap
—
Revenue growth (YoY)
-423.8%
Gross margin
$865K
Free cash flow (USD)
$37.2M
Net debt
14.0%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
4
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 5, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 8, 2026Filing
Incentive Award Plan Amendment
- 8-K eventJul 8, 2026Filing
Company Overview Presentation
- 8-K eventJun 5, 2026Filing
Lease Amendment
- 8-K eventJun 1, 2026Filing
Director Departure
- Insider sellMay 19, 2026Filing
Insider Sell $580 · 10b5-1 PlanHenn Matthew R · See Remarks · $579.8
- Insider sellMay 19, 2026Filing
Insider Sell $444Brady Kelly · See Remarks · $444.3
- Insider sellMay 19, 2026Filing
Insider Sell $595 · 10b5-1 PlanDesRosier Thomas · See Remarks · $594.9
- Insider sellMay 19, 2026Filing
Insider Sell $2K · 10b5-1 PlanShaff Eric D. · Director · $2K
- 8-K eventMay 5, 2026Filing
Earnings Release
- Quarterly reportMay 5, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is Seres Therapeutics, Inc.'s market cap?
Seres Therapeutics, Inc. (MCRB) has a market capitalization of $50.8M.
What is MCRB's P/E ratio?
MCRB trades at a price-to-earnings ratio of 11.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is MCRB's price-to-book (P/B) ratio?
MCRB trades at 1.15 times book value per share.
Are insiders buying MCRB stock?
SEC Form 4 filings show no open-market insider buys at Seres Therapeutics, Inc. in the last 90 days (4 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.